CA-CRATEDB
1.3.2023 14:16:17 CET | Business Wire | Press release
CrateDB, the distributed SQL database company enabling data insights at scale, is pleased to announce the appointment of Lars Färnström as new Chief Executive Officer (CEO). With expansive leadership experience across the software sector, Lars is tasked with taking CrateDB into a new phase of growth as it looks to deliver data-driven decision making to global enterprises.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005068/en/
Real-Time Analytics Database Company CrateDB Names Lars Färnström as New CEO (Photo: Business Wire)
Lars Färnström, CEO, CrateDB - “I am thrilled to join the talented team at CrateDB and help drive the next phase of growth for this innovative database company. CrateDB addresses the urgent need for companies to make data driven decisions in real-time and leverage the power of insight that AI/ML can bring.”
“CrateDB is unique in this sense it allows developers, data engineers and data scientists to use standard SQL to access and query time series data, relational data, semi-structured data, complex files like JSONs, geo-spatial, full text and blobs. CrateDB stores all this critical data in a single unified database and delivers results in real-time, at a scale and with low costs – on-premise, in the cloud and at the Edge. These are unique capabilities any company needs to remain competitive.”
“We are incredibly pleased to announce Lars as our new CEO. After speaking with Lars about his experience and vision for CrateDB, we knew immediately that he is the person to take the company forward. Lars’ knowledge of the software sector, and in particular the ability for data to transform how enterprises operate, will be hugely significant for CrateDB.” - Alois Flatz, Chairman of the Board, CrateDB.
Lars Färnström has more than 25 years of experience in the software industry, where he has held a variety of senior and executive positions in management, sales, marketing, product marketing and program management. He joins CrateDB from C3.ai where he was responsible for the Nordics, Benelux, and Switzerland. Prior to C3.ai, he worked for small, medium, and large enterprises such as HPE, Siebel Systems, GoodData, and Board International where he helped scale their businesses.
For more information about CrateDB, visit www.crate.io.
ENDS
About CrateDB
CrateDB is a real-time analytics database solution, enabling data insights at scale. CrateDB’s ability to ingest and manage massive amounts of data from diverse sources empowers companies worldwide to turn data into business value.
CrateDB was founded in 2013 and operates globally with offices in Germany, Austria, Switzerland and the US. In 2021, CrateDB was named as an Honorable Mention in the 2021 Gartner Magic Quadrant for Cloud Database Management Systems and won the IoT Evolution Industrial IoT Product of the Year Award. Clients maximizing their data potential with CrateDB include ABB, Alpla, Rauch, TGW Logistics, and Bitmovin.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005068/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom